GlassScriptPhysician profile
Steven R Landreth
NPI 1083828545
$8,559.24
in general payments reported to CMS, 2019-2025
25 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $516 · 2021: $669 · 2022: $721 · 2023: $1,441 · 2024: $1,912 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,685 · Entertainment: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,685.00 |
| Entertainment | $1,142.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,015.64 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Optos, INC. | $1,351.60 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $514.84 | 2022-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $465.35 | 2019-2022 | |
| Lkc Technologies, INC. | $365.40 | 2022-2024 | |
| Biotissue Holdings INC. | $359.12 | 2023-2025 | |
| Oyster Point Pharma, INC. | $314.12 | 2022-2023 | Tyrvaya |
| Astellas Pharma US INC | $285.71 | 2023-2025 | Izervay |
| Glaukos Corporation | $276.90 | 2021-2025 | Photrexa Viscous and Photrexa |
| New World Medical,INC. | $273.87 | 2025 | Via360, Streamline, Ahmed Glaucoma Valve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $182.23 | 2020-2021 | |
| Coopervision INC. | $181.41 | 2019-2023 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $131.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $118.26 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avedro INC. | $106.69 | 2019 | |
| Ocular Therapeutix, INC. | $106.64 | 2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $93.53 | 2021 | |
| Dompe US, INC. | $87.23 | 2024 | Oxervate |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Derma Sciences, INC. | $43.73 | 2019 | |
| Abbvie INC. | $36.50 | 2025 | |
| Maculogix, INC. | $28.90 | 2019 | |
| Eyevance Pharmaceuticals LLC | $23.67 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Landreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.